CosmeRNA: Hope or Cope

The launch of CosmeRNA’s androgen receptor (AR) inhibitor ignited a great deal of hope and cope within the hair loss community We are desperate for better options, and the ability to buy one deemed safe and effective by the reputable European and UK regulatory agencies is a dopamine rush only similar to ordering TM on WhatsApp (for research use only). The bulls and the bhairs of the novel treatment each laid their claims to the global hair loss community

The bulls pointed to the results of CosmeRNA’s flagship study–a 4.5% increase in total hair count across a double-blind placebo study with 43 par ticipants. AR–after all–is a known actor in several prominent hair loss pathways, and so inhibiting it by even a small percentage should render a clinical effect. Additionally, CosmeRNA’s approval as a cosmeceutical–even at its high 5 mg/ml dose–leads us to believe that the treatment will likely not have side effects. The bulls are left to exclaim that we may achieve a gold standard in the hair loss market: a growth promoter with very low side effect risk.

The bhairs lament the study’s breadth and depth. Only 22 patients received the 5mg/ml dose, at a significantly different dosing schedule than what CosmeRNA is currently adver tising (1x per week vs 1x per 2 weeks). Three of the four tested disease models–LNCaP cells; human dermal papilla cells; plucked human hair follicles–are worse than the scalp skin model used in our T3/T4 study The study also completely failed to measure the in vivo penetration or genomic changes of CosmeRNA’s active ingredient (AR68)–we don’t know if the treatment reaches or has any effect on our hair bulbs. Standard biopsies of the patients par ticipating in their human unofficial clinical trial–as Dr. Barghouthi conducted for his Ver teporfin tests–would have provided answers for both questions, thus significantly strengthening CosmeRNA’s small dataset.

The biopsies we outline above would have cost no more than $50,000–a small add-on to the likely multi-hundred thousand dollar study run by Bioneer–the nearly billion dollar corporation behind CosmeRNA. Due to CosmeRNA’s inability to produce adequate data, we are left to test it ourselves. We recommend testing CosmeRNA only if one has the money to spend. If you generate the data, please share it with us in the Patient Por tal for HAIR. Those who buy the product have the ability to better evaluate the efficacy of the treatment than any institution today

Contributors: Visangle, BradMish, FollicleThought, Jumpman, Herber t, Tigris, Romeo, Macaque, Pointlol, Andy1, Cook, Copernacus, Endana, Averbs123, Dragan Dabic, Ghter, Gurgeh, Benjels, Fgsfds, and Potential Dingo